Plant Name: Capsicum annuum
Taxonomic Information:
Plant ID: NPO16501
Plant Latin Name: Capsicum annuum
Taxonomy Genus: Capsicum
Taxonomy Family: Solanaceae
Plant External Links:
NCBI TaxonomyDB:
4072
Plant-of-the-World-Online:
316944-2
Used in Medicines:
Country/Region:
Turkey; Italy; Mexico; Indonesia; India; Jordan; NigeriaTraditional Medicine System:
Unani; Indian Folk; Homeopathy; Ayurveda; SiddhaMedicinal Functions:
Antidiarrhoeal; Antiemetic; Antihaemorrhoidal; Antirheumatic; Antispasmodic; Appetizer; Digestive; Irritant; Rubefacient; Sialagogue
Geographical Distribution:
Brazil; Turkey; Madagascar; Italy; Bangladesh; Mali; Cambodia; Bahamas; Ethiopia; Tanzania; Somalia; Peru; Laos; Austria; Nigeria; Bolivia; Cameroon; Cote d'Ivoire; Ecuador; Benin; Ghana; Australia; South Africa; Algeria; Cuba; Togo; Venezuela; Zambia; Cape Verde; Papua New Guinea; Sri Lanka; Guatemala; Zimbabwe; Jordan; Vanuatu; Senegal; Dominican Republic; Belize; United States; Sierra Leone; Eritrea; Maldives; Uganda; Gambia; Philippines; Indonesia; Mauritius; Morocco; Vietnam; Gabon; Guinea-Bissau; Kenya; Honduras; Nepal; Haiti; Pakistan; Angola; Myanmar; Chad; Equatorial Guinea; Tunisia; Mexico; India; Trinidad and Tobago; Botswana; Djibouti; Congo; Colombia; Greece; Burundi; Japan; Niger; Fiji; Comoros
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; FFAR4; ADRA2B; FFAR1; | |
| TSHR; NPSR1; | |
| CDA; ADK; DAO; ALOX12; HSD17B10; NOX4; ALOX15; POLB; | |
| TRPV1; | |
| AXL; MET; FLT3; CDK1; MAPK1; PIM1; KDR; IGF1R; AURKB; | |
| CA12; CA7; CA4; | |
| PPARA; | |
| NR1H4; | |
| MMP12; | |
| HIF1A; TP53; | |
| SLCO1B1; | |
| LMNA; FABP3; FABP5; FABP4; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | DAO | D-amino-acid oxidase | P14920 | CHEMBL5485 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | Unclassified; | GO:0004872; receptor activity | 9.418E-08 | 4.185E-05 | ADORA1, ADORA2A, ADORA3, ADRA2B, AXL, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, NR1H4, PPARA, TRPV1, TSHR |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.761E-07 | 6.848E-05 | ADORA1, ADORA2A, ADORA3, ADRA2B, AXL, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, SLCO1B1, TRPV1, TSHR |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 3.574E-07 | 1.104E-04 | ADORA1, ADORA2A, ADORA3 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 3.599E-07 | 1.104E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 8.552E-07 | 2.306E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.220E-06 | 3.088E-04 | CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.968E-06 | 6.527E-04 | CYP1A2, CYP1B1, CYP2C9, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.589E-06 | 8.843E-04 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.841E-06 | 8.858E-04 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0019858; cytosine metabolic process | 4.841E-06 | 8.858E-04 | CDA, MAPK1 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.841E-06 | 8.858E-04 | ALOX12, ALOX15 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 5.067E-06 | 9.195E-04 | ALOX12, HIF1A, IGF1R, KDR, MAPK1, MET, NOX4, TP53 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 5.507E-06 | 9.910E-04 | ADORA1, ADORA2A, FFAR4, NR1H4, PPARA |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 5.639E-06 | 1.007E-03 | ADORA1, ADORA2A, MAPT |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 6.344E-06 | 1.105E-03 | ADORA1, ADORA2A, CA7, KDR, NPSR1, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:1901652; response to peptide | 1.090E-05 | 1.683E-03 | FABP3, FFAR4, IGF1R, PPARA, TP53, TRPV1, TSHR |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 1.217E-05 | 1.828E-03 | ALOX15, AXL, FABP4, FLT3, HIF1A, MAPK1, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.329E-05 | 1.974E-03 | CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.450E-05 | 2.064E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.450E-05 | 2.064E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.450E-05 | 2.064E-03 | ADORA1, ADORA2A |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.908E-05 | 2.613E-03 | ALOX12, CDK1, FLT3, HIF1A, IGF1R, KDR, MAPK1, MMP12, PIM1, TSHR |
| BP | GO:0009987; cellular process | GO:0051289; protein homotetramerization | 2.187E-05 | 2.922E-03 | CDA, HSD17B10, TP53, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 2.206E-05 | 2.929E-03 | ADORA1, HIF1A, LMNA, NOX4, PPARA, TP53 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.284E-05 | 2.985E-03 | FABP3, FABP4, FABP5 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 2.421E-05 | 3.066E-03 | IGF1R, MAPK1, NOX4, NR1H4, TP53, TRPV1, TSHR |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 2.456E-05 | 3.092E-03 | ADORA1, ADRA2B, CDK1, FLT3, MAPK1, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.734E-05 | 3.345E-03 | ALOX12, ALOX15, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.896E-05 | 3.465E-03 | CYP1A2, CYP2C9 |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 3.078E-05 | 3.643E-03 | MAPK1, MAPT, MET, PPARA, TP53 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 4.733E-05 | 5.077E-03 | MAPT, NOX4, TP53, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 4.820E-05 | 5.095E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 4.872E-05 | 5.101E-03 | HIF1A, KDR, MAPT |
| BP | GO:0008152; metabolic process | GO:1902893; regulation of pri-miRNA transcription from RNA polymerase II promoter | 5.351E-05 | 5.522E-03 | HIF1A, PPARA, TP53 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 6.286E-05 | 6.250E-03 | ADK, AURKB, AXL, CDK1, FLT3, IGF1R, KDR, MAPK1, MET, PIM1, TP53, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.970E-05 | 6.806E-03 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 7.194E-05 | 6.926E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.220E-05 | 6.926E-03 | CYP1A2, CYP2C9 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 8.285E-05 | 7.743E-03 | ADORA1, ADORA2A, ALOX15, AXL, CDK1, CYP1A2, CYP1B1, FABP5, FLT3, HIF1A, KDR, LMNA, MAPK1, PIM1, POLB, PPARA, TP53, TSHR |
| BP | GO:0009987; cellular process | GO:0055082; cellular chemical homeostasis | 8.406E-05 | 7.757E-03 | CA7, HIF1A, MAPK1, NOX4, NPSR1, NR1H4, TP53, TRPV1 |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.009E-04 | 8.971E-03 | FLT3, KDR |
| MF | GO:0005488; binding | GO:0097371; MDM2/MDM4 family protein binding | 1.009E-04 | 8.971E-03 | PPARA, TP53 |
| BP | GO:0065007; biological regulation | GO:0055081; anion homeostasis | 1.033E-04 | 9.104E-03 | CA12, FABP3, NR1H4 |
| BP | GO:0051179; localization | GO:0060341; regulation of cellular localization | 1.181E-04 | 9.986E-03 | ADORA2A, CDK1, HIF1A, LMNA, MAPK1, MAPT, NPSR1, NR1H4, TP53 |
| BP | GO:0009987; cellular process | GO:0001961; positive regulation of cytokine-mediated signaling pathway | 1.192E-04 | 9.986E-03 | AXL, HIF1A, MMP12 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.161E-07 | 4.679E-05 | FLT3, MAPK1, TP53, MET, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 4.528E-06 | 3.041E-04 | KDR, MAPK1, TP53, HIF1A, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.621E-05 | 4.797E-04 | MAPK1, TP53, MET, IGF1R |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 2.651E-05 | 6.538E-04 | ADORA2A, ADORA3, ADORA1, TRPV1, ADRA2B, TSHR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.446E-05 | 4.797E-04 | FABP3, FABP4, FABP5, PPARA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 6.566E-05 | 1.215E-03 | ADORA2A, ADORA1, MAPK1, PPARA, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 8.659E-05 | 1.424E-03 | ADORA2A, KDR, MAPK1, MET, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 6.164E-06 | 3.041E-04 | CA12, CA4, CA7 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.930E-04 | 2.380E-03 | FLT3, MAPK1, HIF1A, MET, TP53, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 9.718E-05 | 1.438E-03 | CYP2C9, ALOX15, MAPK1, ALOX12 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.253E-05 | 6.878E-04 | CYP2C9, CYP1A2, ALOX15 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.269E-04 | 1.708E-03 | ADORA3, ADORA1, MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.498E-04 | 2.641E-03 | FLT3, PIM1, MAPK1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 2.370E-04 | 2.641E-03 | FABP4, ADORA1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 3.685E-04 | 3.356E-03 | MAPK1, TP53, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.234E-04 | 3.481E-03 | PIM1, CYP1B1, MAPK1, TP53, MET |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.205E-04 | 3.162E-03 | CYP2C9, ALOX15, ALOX12 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 4.490E-04 | 3.497E-03 | ADORA3, ADORA1, MAPK1, ADRA2B |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 3.854E-04 | 3.356E-03 | MAPK1, MET, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 7.914E-04 | 4.880E-03 | KDR, MAPK1, TP53, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 5.954E-04 | 4.005E-03 | FLT3, TP53, MET, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 9.159E-04 | 5.261E-03 | KDR, MAPK1, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 9.675E-04 | 5.303E-03 | POLB, CDK1, MAPK1, TP53 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 5.395E-04 | 3.802E-03 | MAPK1, MET, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.184E-04 | 3.802E-03 | CYP2C9, CYP1A2, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 9.243E-04 | 5.261E-03 | MAPK1, TP53, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.410E-03 | 6.955E-03 | KDR, MAPK1, MET, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.221E-03 | 6.456E-03 | CDK1, MAPK1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 7.283E-04 | 4.687E-03 | CYP2C9, CYP1A2, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.410E-03 | 6.955E-03 | MAPK1, HIF1A, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.080E-03 | 9.622E-03 | MAPK1, TP53, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 1.767E-03 | 8.435E-03 | MAPK1, TP53 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ADORA1; ADORA2A; TRPV1; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; MAPK1; CDA; TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; FFAR1; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; MAPT; DAO; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA1; ADORA2A; ADORA3; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; ADRA2B; TRPV1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| NA: NA | GIST | NA | FLT3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA1; ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ADORA2A; ADK; TRPV1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; TP53; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; FLT3; HIF1A; ADORA3; MAPK1; TP53; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| NA: NA | Esophagus sensitivity | NA | TRPV1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; ADORA2A; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; TP53; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; TP53; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
